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Abstract
Genome-wide association  studies (GWAS) have identified more than
50,000  unique  associations  with  common  human  traits.  While  this
represents  a  substantial  step  forward,  establishing  the  biology
underlying  these  associations  has  proven  extremely  difficult.  Even
determining which cell types and which particular gene(s) are relevant
continues to be a challenge. Here, we conduct a cell-specific pathway
analysis of the latest GWAS in multiple sclerosis (MS); which analyzed a
total of 47,351 cases and 68,284 healthy controls and found more than
200 non-MHC genome-wide associations. This analysis identifies pan
immune cell as well as cell-specific susceptibility genes in T cells, B
cells and monocytes. Finally, genotype-level data from 2,370 patients
and 412 controls is used to compute intra-individual and cell-specific
susceptibility  pathways  that  offer  a  biological  interpretation  of  the
individual genetic risk to MS. This approach could be adopted in any
other complex trait for which genome-wide data is available. 
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Introduction
Translating  GWAS discoveries  into  functionally  relevant  biology  has
proven to be highly challenging. The extensive linkage disequilibrium
(LD) which typically flanks common variants means that most GWAS
identified SNPs are likely to be tags for functionally relevant variation
rather than exerting any meaningful effects themselves. Furthermore,
since the vast majority of associations identified by GWAS map to non-
coding regulatory regions it  is  likely  that the underlying functionally
relevant variants only  exert  pertinent  effects on gene expression in
particular  tissues.  1-4 Fortunately,  better  powered  studies,  have
increased  the  number  of  associations  identified  enabling  biological
meaning to be investigated in aggregate (i.e. pathway analysis). In its
simplest  form,  genes  lying  closest  to  the  most  strongly  associated
(lead)  SNP  identified  for  each  association  can  be  grouped  into
pathways  or  specific  functional  memberships  via  the  use  of  pre-
assembled controlled vocabularies (Gene ontology, KEGG, etc).5-8 This
approach can be enhanced by using protein interaction networks to
more rigorously assess which of the candidate genes encode proteins
that physically interact in any particular pathway.9  Using this refined
approach, we and others have been able to show that MS-associated
genes  are  indeed  more  likely  to  interact  in  protein  space.10-12
Furthermore,  this  analysis  can  be  extended  to  include  association
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signals below the genome-wide threshold of significance and thereby
nominate  new  additional  potentially  meaningful  associations.11,13,14
However,  the  networks  of  genes/proteins  identified  by  these
approaches are not cell- or tissue-specific, thus limiting the usefulness
and interpretability of this information. 
With the completion of efforts like the Encyclopedia of DNA elements
(ENCODE)  and the  Roadmap Epigenomics  Project  (REP)  a  wealth  of
information on regulatory elements is now available from hundreds of
cell types and dozens of different tissues, 15,16 raising the possibility of
applying  network-based  approaches  in  a  cell-specific  manner.  We
reasoned this approach would likely be highly informative in diseases
like multiple sclerosis (MS) where substantial numbers of  associated
variants have been identified.  MS is  an autoimmune disease of  the
central  nervous  system  (CNS)  and  leads  to  a  neurodegenerative
process.  Our  recent  GWAS meta-analysis  and  follow-up  study  have
revealed a  total  of  233  genome-wide  significant  associations  and a
further 416 variants potentially associated with MS.17
Here we develop a framework to interpret such associations in the 
context of cell-specific protein networks to identify the most likely 
process(es) affected by the non-MHC associations as a whole. This 
approach involves 1) selecting independently associated signals in 
extended haplotypic blocks; 2) identifying the genomic regulatory 
processes likely to be altered by the polymorphisms in these blocks in 
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a cell-specific manner; 3) computing a cell-specific gene score for 
genes in each associated locus; 4) building cell-specific gene/protein 
networks; 5) Interpreting the biological processes most likely affected 
for each of the cell types studied. We demonstrate this approach in the
latest GWAS meta-analysis in MS involving a total of 47,351 cases and 
68,284 controls. Furthermore, we use genotype-level data from a 
subset of 2,370 cases and 412 controls to identify cell-specific intra-
individual risk pathways. These individualized scores can be used as a 
global risk measure in subsequent associations with more detailed 
phenotypes.  
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Results
Predicted regulatory effects (PRE) of MS-associated variants
We  integrated  genetic  association  signals  from  the  latest  genetic
analysis of MS17 with cell specific information on regulatory elements
available from the ENCODE and Epigenomics Roadmap projects (REP)
to  identify  cell-specific networks  likely  affected by  the susceptibility
variants (Figure 1A, Supplementary Figure 1). We included all genome-
wide (GW) significant single nucleotide polymorphisms (SNPs) together
with their proxies selected at differing LD thresholds (r2>0.5 was used
for the main analysis). 
All regulatory information retrieved for each MS-associated region was
compiled for each cell type in a single master table (Supplementary
dataset  1).  This  catalogue  contains  all  of  the  available  regulatory
features that potentially modulate the expression of each of the genes
mapping to each associated region in a cell-specific manner.  We next
used  this  information  to  build  a  cell-specific,  genetic  regulatory
network  that  constituted  the  basis  of  a  gene  prioritization  scheme
within  each  associated  region  (Figure  1B).  Specifically,  each  gene
within a given locus received a score (PRE) that does not depend solely
on  the  closest  SNP,  but that  is  equal  to  the  weighted  sum  of  all
regulatory  features  potentially  affected  by  variation  at  nearby
associated  SNPs  (See  Methods).  Figure  1C  shows  a  heat  map
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representation of the PREs for all genes (n=2,444) implicated by the
GW significant MS associations for each of the main cell/tissue types
(Individual  PREs for each cell/tissue and GWAS statistical confidence
are listed in Supplementary Dataset 2-28). Two GW significant regions
(10 and 21) are shown in larger detail as representative examples (Fig
1C).  Because  it  integrates  actual  regulatory  information  for  each
associated SNP and those in LD, this approach can prioritize the most
likely genes affected by the same association signals in each cell type
analyzed (Supplementary Dataset 29). In the example, the PREs at the
top  of  Figure  1C  highlight  the  lead  variant  defining  Region  10
(rs6670198,  Chr  1)  and  those  in  LD  which  are  likely  to  affect  the
expression of  FAM213B and  TNFRSF14 in all immune cells (B, T and
monocytes -M-). These SNPs would have almost no effect at all in the
CNS and lungs (L), as MS-associated variants are unlikely to alter their
expression  in  those  tissues.  For  comparison,  a  simple  proximity
approach would have just implicated the FAM213B gene, which, while
being  of  biological  interest,  may  describe  an  incomplete  scenario.
Interestingly,  TNFRSF14 (a member of the TNF receptor superfamily)
encodes  a  protein  involved  in  signal  transduction  pathways  that
activate both inflammatory and inhibitory T-cell immune responses due
to  its  particular  ability  to  interact  with  multiple  ligands  in  distinct
configurations.18
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Another example is provided by region 21, defined by the lead SNP
rs6032662  mapping  to  chromosome  20.  rs6032662  maps  midway
between NCOA5, a tumor suppressor gene, and CD40, which encodes a
well-known member of the TNF-receptor superfamily. This receptor is
essential in mediating a broad variety of  immune and inflammatory
responses including T cell activation, T cell-dependent immunoglobulin
class  switching,  memory  B  cell  development,  and  germinal  center
formation.19 While its expression is highest among antigen presenting
cells  (including  those  derived  from  dendritic  cells  and
monocyte/macrophages) its PRE score is low in the M set (Figure 1C),
indicating  that,  of  the  cells  studied,  MS-associated  variants  only
regulate its expression in B cells. Altogether, these results show that
this approach is a useful strategy to prioritize genes within association
regions.
Protein connectivity among products of MS-associated loci
Previous  studies  have  shown  that  the  proteins  encoded  by  genes
affected by genetic association signals are more likely to interact, in
part  because  they  often  participate  in  the  same  biological
pathways.6,20-22 Thus, we evaluated (for each cell/tissue) how many of
the gene products in MS-risk loci predicted to be positively regulated
(i.e. PRE>25th percentile or PRE-25) also interacted in a human protein
network  containing  15,783  proteins  and  455,321  interactions  (See
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methods) (Figure 2 shows a schematic of this approach). In addition to
the  total  number  of  interactions  we  also  computed  other  relevant
network metrics such as the size of the largest connected component –
LCC– and the number of connections –edges- among nodes within the
LCC. These metrics, if statistically significant, are often good indicators
of true biological networks. We found that, for all immune cell types
analyzed,  the  above  network  metrics  among  GW  associated  gene
products  always  exceeded  those  from  10,000  randomly  generated,
size-matched networks. Specifically, network metrics among the gene
products of GW associated loci were statistically significant for T cells,
B cells and monocytes (Figure 3). The number of interactions among
genes  related  to  the  CNS  were  not  significantly  different  than
expected. One factor likely affecting this result is that in contrast to
immune  cells  (for  which  PREs  were  computed  on  a  cell-specific
manner)  computations  for  CNS  are  the  result  of  25  different  cell
types/anatomical  regions.  This  could  potentially  smooth  the  overall
estimate of  PREs as the various  cell  types within the CNS could be
under  different  regulatory  control.  The  three  significant  networks
(Figure 3A-C) shared several of their genes, thus constituting a core
module (Figure 3D).  The molecular functions of most of these genes
belonged to the binding (36%) and catalytic activity (33%) categories.
Other  functions  were  receptor  (13%),  signal  transduction (6%),  and
structural molecule (10%). A PANTHER analysis revealed these genes
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belong  to  JAK/STAT,  IFNgamma,  interleukin,  and  integrin  signaling
pathways,  among  others.  Altogether,  our  analyses  suggest  that
susceptibility to MS stems from a core of processes that can be active
in  any  of  several  immune-related  cell  types.  These  findings  are  in
agreement  with  the  “omnigenic”  model  of  inheritance  of  complex
diseases,  posing  that  gene  regulatory  networks  are  sufficiently
interconnected such that all genes expressed in disease-relevant cells
are liable to affect the functions of core disease-related genes.23
As predicted by the omnigenic model,  we noted that several  genes
were  only  present  in  some cell  types  but  not  others.  For  example,
CD28 was only present in the T cell  network,  ELMO1 in B cells and
MERTK in the monocyte/macrophage lineage.  CD28 is located on the
surface  of  T  cells  and  provides  a  required  co-stimulatory  signal  to
trigger  their  activation  after  engagement  of  the  MHC-antigen-T  cell
receptor  trimolecular  complex.24  ELMO1 encodes  a  cytoplasmic
adaptor  protein  that  interacts  with  DOCK family  guanine nucleotide
exchange factors to promote activation of the small GTPase RAC, thus
enabling lymphocyte migration.25  The MERTK gene encodes a receptor
tyrosine kinase that transduces signals from the extracellular matrix
into the cytoplasm regulating many physiological processes including
cell survival, migration, differentiation, and phagocytosis of apoptotic
cells (efferocytosis). Specifically,  MERTK plays several important roles
in  normal  macrophage  physiology,  including  regulation  of  cytokine
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secretion  and  clearance  of  apoptotic  cells.26 These  observations
suggest that, in addition to the core susceptibility module, at least part
of the risk is cell type-specific. 
We  next  performed  a  sensitivity  analysis  by  testing  separately
genome-wide  (GW),  statistically  replicated  (SR)  and  non-replicated
(NR)  effects  (see  Methods)  SNP  sets  at  three  different  LD  cut-offs
(r2>0.1, r2>0.5 and r2>0.8) and three PRE thresholds (PRE-10, PRE-25
and PRE-50) (Supplementary Dataset 30). As anticipated, although the
most significant network metrics were seen in the analysis based on
GW  signals  (Supplementary  Figure  2,  panel  A),  some  significant
network metrics were also seen in the analysis based on the SR SNPs
(Supplementary Figure 2, panel B). This confirms that in well powered
studies variants with evidence for association just short  of  genome-
wide significance may still  represent real  effects.14  In contrast,  the
connectivity  of  networks  obtained  with  SNPs  from  the  NR  set  was
usually  not  significantly  higher  than  that  of  random  networks
(Supplementary Figure 2, panel C). As expected, including the wider
range of SNPs implicated by relaxing the LD threshold down to r2>0.1
resulted in less significant network metrics, suggesting that including
less robust proxies introduced more noise than signal. 
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Individualized PRE correlate with gene expression
The detailed mapping of regulatory information for each SNP suggests
that if PRE are computed for a given cell type in a single individual
based  on  the  carriage  of  relevant  risk  alleles,  these  values  should
capture a non-negligible proportion of the variance in gene expression
in  that  cell  type.  To  test  this  hypothesis,  we  interrogated  the
expression of the entire transcriptome of FACS-sorted CD4+ T cells, and
CD14+ monocytes from 25 MS patients by RNAseq and then assessed
the correlation of their genotype dependent PRE and their actual gene
expression in each cell type separately. Our results showed that the
correlation  observed was in  all  cases significantly  higher  than what
would  be  expected  by  chance  if  these  metrics  were  independent.
Furthermore,  the  computed correlations  were  always  higher  for  the
matching cell  type (CD4/CD8 expression with T cells  PRE and CD14
expression with monocytes PRE) (Table 1).   The average correlation
between RNA expression and PRE within the same cell type was 0.331
(CD4 vs. T cells,  p<10-300,  linear regression), 0.324 (CD8 vs. T cells,
p<10-300, linear regression), and 0.246 (CD14 vs. monocytes, p<10-300,
linear  regression),  representing a  significantly  higher  than expected
value for each cell type. Correlations between PRE and RNA expression
of  mismatched  cell  types  were  significantly  lower.  These  results
suggest that the computation of PRE can be applied to single patients
and individual scores can be generated for each of them. 
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We then used the genotype-level data from one of the GWAS datasets
(UCSF, Supplementary Dataset 31), composed of 2,370 patients and
412 controls,  to compute cell-specific risk scores for each individual
using the same pipeline used for the population-level data. Rather than
considering all 200 associations, this personalized approach takes into
account the specific risk alleles present in each individual  and thus
enables  exploration  of  subject  heterogeneity  in  a  biological  context
and in a cell specific manner. Hierarchical clustering of subjects and
heatmap visualizations of the PRE of genes under regions 9, 49 and 53
(r2>0.5) for all cell types in this subset of cases and controls are shown
as an example (Figure 4). The heterogeneity across individuals in the
PRE of a given gene can be readily seen for all cell types. As expected
for common variants, cases and controls (denoted by red and green
horizontal bars in the leftmost column) do not cluster separately within
any  single  association  region.  This  analysis  provides  a  visual
representation  of  which  genes  are  most  likely  affected  by  common
variants  associated  with  the  disease  in  those  individuals,  in  a  cell-
specific manner. The PRE for most genes in each heatmap show ample
variability across individuals, highlighting genetic differences in their
susceptibility to MS at this locus. These maps also reveal which genes
are  most  likely  to  be  affected  in  each  cell  type  by  these  common
alleles. For example, while associated variants near the gene  EOMES
(region 9) potentially modulate its expression in T cells, this gene is
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less regulated in B cells and monocytes and strongly silenced in CNS
(Figure 4A). This is consistent with its function as a critical transcription
factor  in  T  cell  differentiation.27,28 Interestingly,  higher  PRE of  these
variants are observed for Th2 cells than for any of the other subsets
analyzed.  Previous  reports  revealed  that  EOMES expression  limits
FOXP3 induction, thus effectively reducing Treg populations.29 Genomic
variation at this locus resulting in dysregulated EOMES expression in T
cells and NK cells might be a critical mediator of the risk to MS.30  
Another interesting example is  the high PRE observed for  the gene
CD40 (region 21) preferentially in B cells for most subjects (Figure 4B,
pink boxes). This finding is consistent with the critical role of CD40 in B
cell development and maturation, and indicates that MS risk affecting
B cell  biology  is  higher  in  some subjects  than others.  Furthermore,
individuals carrying the risk variants within  CD40 (rs4810485*T) have
been reported to express lower levels of CD40 in the surface of their B
cells and lower IL-10 levels.31 This could carry therapeutic implications
considering  the  prominent  role  of  B  cell  depletion  therapy  in  this
disease.32,33 Another signal revealing B cell involvement in MS risk is
the high PRE of all members of the Fc receptor-like (FCRL) gene family
in region 53 (Figure 4C, yellow boxes) preferentially in B cells for most
subjects,  consistent  with  the  function  of  these  gene  family  as
regulators of proliferation in B cells and phagocytosis.34 
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Intra-individual risk networks are more connected in MS 
Finally,  we integrated individual  risk regulatory scores with a global
protein  interactome  to  compute  intra  individual,  cell  specific  risk
networks. We hypothesize that these networks would provide a step
forward  in  the  description  of  aggregate  personalized  risk  scores  by
representing risk  in  a  biologically  relevant  manner.35,36 Furthermore,
building  risk  profiles  with  pathway  and  cell  specific  information
describes  more  accurately  the  biology  potentially  affected  by  risk
variants inherited by a particular individual. We also hypothesized that
similarly to what we observed for cases and controls at the population
level, more interactions among proteins encoded by risk loci would be
observed for cases than for controls. This was indeed the case, as we
observed  statistically  significant  differences  between  cases  and
controls  for  the  three  main  cell  types  tested  (the  CNS  was  not
significant  as  shown  in  Figure  5A  and  Supplementary  Figure  3)
(Supplementary  Dataset  32).  The  largest  number  of  intra-individual
interactions  among  gene  products  with  high  PRE  was  observed  in
monocytes, followed by T cells, B cells and the CNS (Figure 5A shows
results for PRE-25).  This is  consistent with the larger significance of
these  risk  networks  observed  at  the  population  level  (Figure  3).
Interestingly,  PRE  values  correlate  with  the  global  polygenic  risk
(Supplementary Figure 4) but it uniquely enables identification of high-
risk  and  low-risk  individuals  in  a  cell-specific  manner.  Figure  5B
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highlights four case:control pairs with different risk profiles in each of
the  four  main  cell  types/tissues  analyzed.  For  example,  subject
201100870 (case) is at the 99th percentile of the distribution of network
edges for monocytes (120 nodes and 271 edges). In contrast, subject
20020214 (control) is at the 1st percentile (61 nodes and 98 edges). 
Another  interesting  observation  emerging  from this  analysis  is  that
subjects  at  the  extremes  of  the  distribution  of  intra-individual
interactions (a proxy for their overall risk) can be identified for each
cell  type.  For  example,  subject  201327986 has 110 nodes and 190
edges in this subject’s B cell risk network (blue box), corresponding to
the  99th percentile  of  all  cases  (Figure  6).  In  contrast,  the
corresponding percentile of  the number of  edges in his T,  M and C
(red/green/yellow)  networks  is  substantially  lower  (47th/49th/66th).  In
line with results observed at the population level, individual CNS risk
networks are consistently smaller and less connected than those from
B  cells,  T  cells  and  monocytes.  Although  CNS  is  still  the  least
connected network in subject 201101897, with 118 edges in its CNS
risk network (yellow box), it ranks in the 99th percentile of all cases. In
contrast the percentile connectivity of T cell (51st), B cell (29th) and M
(75th) risk networks for this subject rank noticeably lower.  
While the number of interactions (edges) among proteins encoded by
genes in associated loci  was variable across cell  types, on average,
more interactions were observed for cases than for controls in all cell
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types  studied.  Supplementary  Figure  3  shows  the  significance  of
testing  different  network  parameters  between  cases  and  controls
across a wide range of conditions. Similar to what we observed at the
population level,  significant effects were also seen for loci  with less
than genome-wide evidence for association, suggesting that some of
those variants considered less strongly significant, also confer risk. 
In summary, this analysis underscores the notion that total MS risk is
not only carried by accumulation of risk alleles, but also by how the
genes and proteins affected by those polymorphisms interact within
each cell type. We anticipate this model could apply to other common
diseases. 
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Discussion
In  this  work,  we  provide  evidence  that  integration  of  associated
variants  from  GWAS  with  regulatory  information  and  protein
interactions,  provide  plausible  models  of  disease pathogenesis.  This
approach  not  only  offers  a  data-driven  solution  to  prioritize  which
genes within a locus are most likely affected by the risk variant(s) but
also provides an interpretable  model  of  risk in  a  cell/tissue specific
manner.  While  the  PRE  scores  computed  here  are  significantly
correlated with actual gene expression from the corresponding cells,
the correlation is partial, thus underscoring a potential limitation in our
approach, and of available data. However, the statistically significant
results obtained for genes and pathways known to be involved in MS
further validates this approach. Indeed, the models presented here are
consistent  with  MS  genetic  risk  being  driven  by  the  long-term
alteration of cellular pathways primarily in monocytes, but also in the B
and T cell arms of the human adaptive immune response. The smaller
but  not  negligible  contribution  of  CNS  pathways  to  MS  risk  is  in
agreement  with  our  previous  analysis17 which  identified  the
monocyte/macrophage/microglia axis as a key player in directing the
autoimmune  process  to  the  CNS.  However,  an  important  caveat,
particularly affecting results for this compartment, must be taken into
account:  for  this  analysis,  the  CNS  group  was  composed  of  a
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heterogeneous  ensemble  of  purified  primary  cells,  established  cell
lines  and  dissected  specimens  from  specific  anatomical  regions  as
available in the ENCODE and REP datasets. Although all derived from
CNS tissue, it is highly likely that different regulatory mechanisms are
at play in each cell type (in some cases resulting in drastically different
expression  patterns),  thus  somehow  confounding  the  overall  CNS
signature computed here. Thus, the detected effect of MS-associations
which map to the CNS could represent the lower boundary of a more
widespread  phenomenon.  A  more  detailed  CNS-specific  data  set
containing  genome-wide  regulatory  element  information  might  be
needed to address this question in larger detail. 
In the last few years, several post-GWAS pathway approaches such as
DEPICT37,  FUMA38 and PASCAL39 have been proposed and utilized to
interpret  and  integrate  summary  statistics  into  a  biologically
meaningful model. While sharing some of the basic characteristics of
previous approaches, our method features a set of unique properties,
most  notably  the  introduction  of  data-driven  regulatory  effects  of
associated variants (and those in LD), the ability to create cell-specific
networks,  and  the  computing  of  individual  disease  burden  maps
(Supplementary Table 1). Given that each method produces a different
output,  it  is  not  possible  to  directly  compare  these  approaches.
However, the first and arguably most important step in all these tools
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(including  ours)  is  to  compute  the  SNP  to  gene  values.  A  basic
comparison of these three tools shows that the exact same genes were
prioritized for  almost half  of  all  non-HLA associated loci  (97/200).  A
closer look revealed that our method was the only one that called at
least one gene per associated locus, and produced gene prioritization
sets  with  the  least  ambiguities  (Supplementary  Table  2  and
Supplementary Figure 5). 
Recent  evidence  has  emerged  that  polygenic  risk  scores  for
schizophrenia  associate  with  therapeutic  response  to  Lithium-based
therapies40. Similar approaches are being tested for other psychiatric,
oncological  and  cardiovascular  diseases  41-45.  The  observation  that
some risk variants only affect expression of a given gene in one cell
type but  not  in  others,  may at  least  in  part,  underlie  the observed
clinical heterogeneity in the MS population. Thus, when this approach
is implemented at the individual level, specific risk profiles can be built
for each subject with MS. We speculate that in the near future this
information could also be used as the basis to develop individualized
risk  scores,  or  to  derive  personalized  approaches  to  therapy.  For
example,  a  subject  with  high  B  cell  genetic  risk  may  be  a  good
candidate for B cell depletion therapies, while a subject with a high T
cell  risk  may  benefit  the  most  from immunomodulatory  drugs  that
target T cell function or migration into the CNS.   
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This  cell-specific  pathway approach  can be  extended to  any  set  of
SNPs of interest in any condition at both population (summary) and
individual (genotype) levels. 
Methods
Predicted regulatory effects (PRE)
Genome-wide  regulatory  elements  from  ENCODE  and  REP  were
collected from regulomeDB46 (which contains  more than 400 million
genomic  regulatory  features  collected  from  400  cell  and  tissues;
Supplementary Table 3) for all non-MHC independent effects (SNPs).17
Specifically,  single nucleotide polymorphisms (SNP) corresponding to
all non-MHC genome-wide (GW) (n=200; Supplementary Dataset 33),
statistically replicated effects (SR) (n=416; Supplementary Dataset 34)
and non-replicated effects (NR) (n=3695; Supplementary Dataset 35)
were extracted for analysis GW, SR and NR as defined previously17).
The 200 GW effects were distributed in 156 unique regions (44 regions
contained multiple independent effects). Similarly, the 416 SR effects
were distributed in 354 unique regions (62 regions contained multiple
independent effects) and the 3,695 NR effects were distributed among
1,883 unique regions (1,812 regions contained multiple independent
affects). Three sets of SNPs were created for each region according to
their  r2 with  their  corresponding  main  effect  (r2≥0.8,  r2≥0.5  and
r2≥0.1). 
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A  python  tool  was  written  to  automatically  fetch  data  from
RegulomeDB for these SNPs in all three lists (totaling 538,826 SNPs).
Similarly,  data for SNPs in different levels of  LD (r2>0.8,  r2>0.5 and
r2>0.1)  with  each  primary  effect  were  also  retrieved  using
chromosomal positions. The main analysis was performed using r2≥0.5
whereas the other sets were only used for the sensitivity analysis. In
total, 538,826 SNPs were included in the analysis. 
To  investigate  the  effect  of  SNPs across  different  cell  types  and to
assess  which  gene  has  most  potential  of  being  regulated  across
various  cell  types,  we  grouped  the  cell  types  present  in  ENCODE
(Supplementary Table 4) and REP (Supplementary Table 5) into four
major cell types (buckets). Specifically, these were B cells, T cells, CNS
(central nervous system), and M (monocytes). T cell subsets (Th1, Th2,
Th17, and Treg) were also analyzed as a separate group. We also built
a dataset from lung (L, a cell type/tissue not considered to play a major
role in MS susceptibility) as a control. Cancer cell lines were excluded
for this analysis. 
Regulatory  elements  were  grouped  into  2  major  classes:  PEX
(promoter/enhancer/activator)  and R (repressors/inactivators).  Cell  or
tissue of  origin  was  recorded  for  each regulatory  feature,  and  cell-
specific information was grouped into three main cell types (B cells, T
cells, monocytes) and one tissue (CNS) that are of interest in MS.  In
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total, 25 brain regions were considered (15 from ENCODE and 10 from
REP). In addition, T cell subsets deemed relevant in the pathogenesis
of  MS  (Th1,  Th2,  Th17,  and  Treg)  were  also  analyzed  separately.
Primary cells and cell lines from a tissue not known to be involved in
MS (lung, L) were included as control. In addition, eQTL data for T cells
and monocytes from the IMMVAR project47 were integrated into the
PRE  computations.  The  HTML  data  from  the  scrapped  output  was
parsed to populate data present in regulomeDB tables. A master table
was then compiled with each field of regulomeDB data for all 538,826
SNPs. 
Multiple regulatory features were considered including protein binding,
transcription  factor  binding  sites  (TFBS),  promoters,  enhancers,
insulators,  histone  modifications,  and  DNAse  hypersensitive  regions
(DHS).  We  classified  these  into  three  broad  groups  representing
promoter/enhancer/transcription  (PEX),  inert/quiescent  (ZQI),  and
repressor (R, Supplementary Table 6).  We next computed weighted
SNP-based scores based on the genotype and number of risk alleles to
quantitate  the  regulatory  influence  of  variation  at  each  SNP.  The
weights were counted as positive if there was evidence that the region
promotes  transcription  and  as  negative  if  there  was  evidence  of
repression. The weights were then normalized by the total number of
experiments conducted for each respective cell type to remove bias
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against  well-studied cell  types.  These weighted weights  (WW) were
summed up across SNPs resulting in a sum of weighted weights (SWW,
or predicted regulatory effect -PRE-) per gene per region in each cell
type. The WW concept derives from the fact that the sum of the effects
of neighboring SNP to a given gene is weighted twice. The first time we
weight the number of experiments reported in ENCODE or REP for a
given SNP-gene pair (e.g. we assign more value to a relationship that
has been reported in 10 independent experiments, to another that has
been reported just once). The second time, we weight the evidence
stemming from all SNPs nearby a gene (depending on the LD structure
there could be ~100 SNP near a given gene).  A gene with a positive
score indicates there is evidence that the region containing the MS-
associated  SNP(s)  is  actively  influencing  its  transcription  in  that
particular cell type and vice-versa. 
All computations were performed in parallel using the 7,400-core QB3
computer cluster at UCSF.
Protein  interaction  network-based  pathway  analysis
(PINBPA)
An experimentally determined human protein interactome consisting
of  15,783  nodes  and  455,321  edges  was  used  for  this  part  of  the
analysis.21 We loaded the network into Cytoscape48 and created cell-
specific sub-networks using gene expression values from elsewhere.
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Specifically,  we  filtered  interactions  realized  only  by  gene  products
expressed in a given cell  type, by using RNAseq expression profiles
from Kitsak et al.49 Thus, for the T cell interactome, we only retrieved
interactions  between proteins  known to be expressed by any T cell
subset  present  in  Kitsak  et  al.  In  the  case  of  CNS,  while  gene
expression data is sufficiently granular (profiles for different brain cell
types  and  regions  exist),  epigenomic  data  for  CNS  cells/tissues  in
ENCODE or REP is very sparse, thus we decided to merge all data into
a single CNS category.
Next,  we  loaded  the  gene-level  PRE  for  each  cell  type  as  node
attributes  and  conducted  a  topological  analysis  by  selecting  the
subnetwork  corresponding  to  the  largest  connected  component  of
nodes with positive PRE (those with negative scores are assumed not
to be expressed, and thus not to be active players of the interactome).
To eliminate noise from very small or loosely unconnected networks,
only  those  with  more  than  15  nodes  were  considered.  Sensitivity
analysis was performed by defining different thresholds on PRE values
(10th,  25th,  50th percentiles) and building networks with only proteins
exceeding these thresholds (Supplementary Fig S1). Individual network
analysis  was  performed considering  differing  sets  of  the  potentially
associated SNPs  identified  in  our  recently  completed  meta-analysis;
those SNP that showed statistically significant evidence of replication
and reached genome-wide significant in the final  combined analysis
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(GW), those that showed statistically significant evidence of replication
but  did  not  reach  genomewide  significance  in  the  final  combined
analysis (SR) and those failing to show statistically significant evidence
of replication (NR). For each cell type, the number of nodes and edges
of each subnetwork and that of its largest connected component were
computed. The statistical significances were computed by comparison
against  a  background  distribution  of  10,000  networks  of  equal  size
sampled randomly from the same PPI.
Cell-specific transcriptomes 
This  work  was  approved  by  the  Institutional  Review  Board  at  the
University of  California  San Francisco (IRB# 10-00104).  PBMCs were
obtained from 25 individuals  by Ficoll  method using Vacutainer CPT
tube  (BD  Biosciences).  Subjects  were  consented  according  to
institutional (UCSF) review board (IRB) guidelines. Three different cell
subsets (CD4+ and CD8+ T cells, CD14+ monocyte) were sorted into RLT
buffer using a MoFlo Astrios cell  sorter (Beckman Coulter).  Helper T
cells were defined as CD3+CD19-CD4+, cytotoxic T-cell were CD3+CD19-
CD8+,  and  monocytes  were  sorted  as  CD14+ cells.  Total  RNA  was
isolated from sorted cell subsets using RNeasy Mini kit (Qiagen) and
assessed  RNA  quality  using  Agilent  2100  Bioanalyzer  (Agilent
Technologies). 3’mRNA-Seq libraries for all cell subsets were prepared
from 100 ng total RNA using QuantSeq kit (Lexogen) according to the
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manufacturer’s  instructions  and sequenced 50-bp single-end on  the
HiSeq 4000 (Illumina).  Sequence reads were mapped to the human
genome  reference  (GRCh38)  with  Gencode  annotation  (r26)  using
STAR aligner.50 Reads were normalized by median of ratios using the
DEseq2 package.51 The  R function  featureCounts was used to obtain
gene-level read counts.52
We selected overlapping genes between RNA-Seq gene counts and PRE
scores, and Pearson’s correlation test was performed using the cor.test
function  in  R.  The  significance of  the  correlation  was  confirmed by
permutation testing (n=1,000).
Acknowledgements:
This investigation was supported in part by the following sources:
NIH/NINDS awards R01NS088155 and 1R01NS099240, the Valhalla Charitable
Foundation,  and  the  Heidrich  Family  and  Friends  Foundation  (Sergio  E.
Baranzini). US National Multiple Sclerosis Society (TA 3056-A-2), the Harvard
NeuroDiscovery  Center  and  an  Intel  Parallel  Computing  Center  award
(Nikolaos  A.  Patsopoulos).  Swedish  Medical  Research  Council;  Swedish
Research  Council  for  Health,  Working  Life  and  Welfare,  Knut  and  Alice
Wallenberg  Foundation,  AFA  insurance,  Swedish  Brain  Foundation,  the
Swedish  Association  for  Persons  with  Neurological  Disabilities.  Cambridge
NIHR Biomedical Research Centre, UK Medical Research Council (G1100125)
and the UK MS society (861/07). NIH/NINDS: R01 NS049477, NIH/NIAID: R01
27
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
AI059829,  NIH/NIEHS:  R01  ES0495103.  Research  Council  of  Norway  grant
196776  and  240102.  NINDS/NIH  R01NS088155.  Oslo  MS  association.
Research  Council  KU  Leuven,  Research  Foundation  Flanders.  AFM,  AFM-
Généthon,  CIC,  ARSEP,  ANR-10-INBS-01  and  ANR-10-IAIHU-06.  Research
Council  KU  Leuven,  Research  Foundation  Flanders.  Inserm  ATIP-Avenir
Fellowship and Connect-Talents Award.  German Ministry for Education and
Research,  German  Competence  Network  MS  (BMBF  KKNMS).  Oslo  MS
association, Research Council of Norway grant 196776 and 240102. Dutch MS
Research  Foundation.  TwinsUK is  funded  by  the  Wellcome  Trust,  Medical
Research Council, European Union, the National Institute for Health Research
(NIHR)-funded  BioResource,  Clinical  Research  Facility  and  Biomedical
Research Centre based at Guy’s and St Thomas’  NHS Foundation Trust in
partnership with King’s College London. German Ministry for Education and
Research,  German  Competence  Network  MS  (BMBF  KKNMS).  Italian
Foundation  of  Multiple  Sclerosis  (FISM).  NMSS  (RG  4680A1/1).  German
Ministry  for  Education  and  Research,  German  Competence  Network  MS
(BMBF KKNMS). Lundbeck Foundation and Benzon Foundation. 
28
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
Complete Author List:
International multiple sclerosis consortium
Lohith Madireddy1, Nikolaos A. Patsopoulos2,3, Chris Cotsapas4,5, Steffan
D. Bos6,7,  Ashley Beecham8, Jacob McCauley8,9 Kicheol Kim1, Xiaoming
Jia1,  Adam  Santaniello1,  Stacy  J.  Caillier1,  Till  F.  Andlauer10,11,  Lisa
Barcellos12,  Tone  Berge7,13,  Luisa  Bernardinelli14,  Filippo  Martinelli-
Boneschi15,16, David R. Booth17, Farren Briggs18, Elisabeth  G  Celius7,19,
Manuel  Comabella20,  Giancarlo  Comi21,  Bruce  A.C.  Cree1,  Sandra
D'Alfonso22, Katrina Dedham23, Pierre Duquette24, Dardiotis Efthimios25,
Federica  Esposito21,  Bertrand  Fontaine26,27,  Christiane  Gasperi10,  An
Goris28,  Bénédicte  Dubois28,  Pierre-Antoine  Gourraud29,30,  Georgios
Hadjigeorgiou31,  Jonathan  Haines18,  Clive  Hawkins32,37,  Bernhard
Hemmer10, Rogier Hintzen33,34, Dana Horakova35, Noriko Isobe36, Seema
Kalra32,37, Jun-ichi  Kira36, Michael Khalil38, Ingrid Kockum39, Christina M.
Lill40,41,  Matthew R.  Lincoln4,  Felix  Luessi40,  Roland  Martin42,  Annette
Oturai43, Aarno Palotie44,45, Margaret A. Pericak-Vance8,9, Roland Henry1,
Janna Saarela44,  Adrian  Ivinson46,  Tomas Olsson39,  Bruce V.  Taylor47,
29
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
Graeme J. Stewart17, Hanne F. Harbo6,7, Alastair Compston48, Stephen L.
Hauser1, David A. Hafler4, Frauke Zipp40, Philip  De Jager3,49, Stephen
Sawcer48, Jorge R. Oksenberg1, Sergio E. Baranzini1,50
Affiliations
1  Weill  Institute  for  Neurosciences,  Department  of  Neurology,
University of California San Francisco, San Francisco, CA, 94158, USA.
2  Systems  Biology  and  Computer  Science  Program,  Ann  Romney
Center  for  Neurological  Diseases,  Department  of  Neurology,  and
Division  of  Genetics,  Department  of  Medicine,  Brigham & Women’s
Hospital, Harvard Medical School, Boston, MA, 02115, USA.
3 Broad Institute of Harvard. University and Massachusetts Institute of
Technology, Cambridge, MA, 02142, USA.
4 Department of Neurology, Yale School of Medicine, 300 George St,
New Haven, CT, 06511 USA.
5 Department of  Genetics,  Yale School  of  Medicine,  300 George St,
New Haven, CT, 06511 USA.
30
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
6 Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway.
7  Department  of  Neurology,  Oslo  University  Hospital,  Oslo,  0424,
Norway.
8 John P. Hussman Institute for Human Genomics, University of Miami,
Miller School of Medicine, Miami, FL, 33136, USA.
9 Dr. John T. Macdonald Foundation Department of Human Genetics,
University of Miami, Miller School of Medicine, Miami, FL, 33136, USA.
10  Department  of  Neurology,  Klinikum  rechts  der  Isar,  School  of
Medicine, Technical University of Munich, 81675 Germany. 
11 Munich Cluster for Systems Neurology (SyNergy), Munich, 81377,
Germany.
12  Division  of  Epidemiology,  School  of  Public  HealthUniversity  of
California, 324 Stanley Hall, MC#3220, Berkeley, CA, 94720, USA.
13 Department of Mechanical, Electronics and Chemical Engineering,
Oslo Metropolitan University, Oslo, 0167, Norway.
31
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
14 Section  of  Biostatistics,  Neurophyisiology  and Psychiatry,  Unit  of
medical and genomic statistics, Universita of Pavia, Pavia, 27100, Italy.
15 Department of Biomedical Sciences for Health, University of Milan,
Milan,  20133,  Italy.
16 MS Research Unit and Department of Neurology, IRCCS Policlinico
San Donato, San Donato Milanese, Milan, 20097, Italy.
17  Faculty  of  Medicine,  Westmead  Clinical  School,  The  Westmead
Institute for Medical Research, Sydney, NSW, 2145, Australia.
18 Department of Quantitative and Population Health Sciences, School
of Medicine, Case Western Reserve University, Cleveland, OH, 44106,
USA.
19  Institute  of  Health  and  Society,  University  of  Oslo,  Oslo,  0318,
Norway.
20 Servei de Neurologia-Neuroimmunologia. Centre d’Esclerosi Múltiple
de  Catalunya  (Cemcat),  Institut  de  Recerca  Vall  d’Hebron  (VHIR),
32
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
Hospital  Universitari  Vall  d’Hebron,  Universitat  Autònoma  de
Barcelona, Barcelona, 08035, Spain.
21 Department of Neurology. San Raffaele Scientific Institute, Milan,
20132, Italy.
22  Department  of  Health  Sciences,  UPO University,  Novara,  28100,
Italy.
23 Department of Clinical Neurosciences. Neurology Unit, University of
Cambridge, Cambridge, CB2 1QW, UK.
24 Faculté de médecine, MS Clinic Centre Hospitalier de l’, Université
de Montréal. Université de Montréal Montreal, Montreal, QC H3A 1G1,
Canada.
25 Department of Neurology, Laboratory of Neurogenetics, University
of Thessaly, University Hospital of Larissa, Larissa, 412 23, Greece.
26 Department of Neurology, University Hopital Pitié-Salpêtrière, Paris,
75013, France.
33
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
27 UMR 1127, Sorbonne-Université, INSERM, University Hopital  Pitié-
Salpêtrière, Paris, 75013, France.
28  KU  Leuven  Department  of  Neurosciences,  Laboratory  for
Neuroimmunology, Leuven, 3000, Belgium.
29  Université  de  Nantes,  INSERM,  Centre  de  Recherche  en
Transplantation  et  Immunologie,  UMR  1064,  ATIP-Avenir,  Equipe  5,
Nantes, F-44093, France.
30 CHU de Nantes, INSERM, CIC 1413, Pôle Hospitalo-Universitaire 11:
Santé Publique, Clinique des données, Nantes, F-44093, France.
31  Department  of  Neurology,  Medical  School,  University  of  Cyprus,
Nicosia,  587G+X2,  Cyprus.
32 Institute for Science & Technology in Medicine,  Keele University,
Keele, ST5 5GB, UK.
33 Department of Neurology, Erasmus MC Dr Molewaterplein 40, 3015
GD Rotterdam, 3015GD, The Netherlands.
34
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
34 Department of Immunology, Erasmus MC, Rotterdam, 3015 GD, The
Netherlands.
35 First Faculty of Medicine, Department of Neurology and Center of
Clinical  Neuroscience,  Charles  University  and  General  University
Hospital, Prague, 3CFG+RJ, Czech Republic.
36  Department  of  Neurology,  Kyushu University,  Kyushu,  812-0053,
Japan.
37  Royal  Stoke  MS  Centre  of  Excellence,  University  Hospital  North
Midlands, Stoke-on-Trent, ST4 6QG, UK.
38 Department of Neurology, Medical University of Graz, Graz, A-8036,
Austria.
39  Department  of  Clinical  Neuroscience  and  Center  for  Molecular
Medicine, Karolinska Institutet, Stockholm, 171 76, Sweden.
40  Department  of  Neurology,  University  Medical  Center  of  the
Johannes Gutenberg University Mainz, Mainz, 55131, Germany.
35
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
41 Genetic and Molecular Epidemiology Group, Lübeck Interdisciplinary
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Figure Legends
 
Figure 1.  Overall  strategy and computation of  the predicted
regulatory effect (PRE) in MS-associated loci. 
A.  GWAS  signals  were  integrated  with  cell-specific  regulatory
information to compute PRE at both population and individual level. In
a second stage, genes with high PRE at each of the cell types analyzed
were identified in a human protein interactome (PPI) and sub-networks
of enriched genes (proteins) were extracted.   B. Each MS-associated
SNP and those in LD were used as query in RegulomeDB. For each SNP,
the all regulatory features were annotated and classified according to
type  and  cell  of  origin.  A  graph  connecting  every  queried  SNP
(crosses),  the  regulatory  feature  (diamonds),  and  the  target  gene
(circles)  was  created  and  the  number  of  experiments  supporting  a
particular  regulatory  feature  was  used  as  weight  (numbers  next  to
SNP). Finally, a PRE score was computed for each gene by summing up
weights from all incoming regulatory signals for each of the cell types
analyzed.  C. Heatmap represents the PRE of all genes under GW MS-
associated loci for cells of interest. Rows represent genes, and columns
denote cell  types.  Colors  indicate positive (red), neutral  (white)  and
negative  (blue)  PRE  values.  Two  representative  regions  are
highlighted.  Region  10  (associated  SNP:  rs6670198,  green  box)
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highlights  immune-specific (B,  T and M) regulation of  FAM213B and
TNFRSF14.  In  contrast,  region  21  (associated  SNP  rs6032662,  blue
box), shows high PRE only for  CD40 in B cells. C: CNS; L: lung; T: T
cells; M: monocytes; B: B cells. This analysis represents all SNPs with
an r2>0.5 of the main GW effect.   
 
Figure 2. Network connectivity analysis.  The PRE of genes were
loaded as  attributes  in  a  protein  interactome.  In  the  central  panel,
genes with a PRE above the 95th percentile of their respective cell-
specific distributions  are visualized (M:  monocyte,  green;  T:  T  cells,
red; B: B cells, blue, C: CNS, yellow). For each cell type, the number of
edges in the sub-network composed of interacting proteins with PRE
above  the  threshold  was  analyzed.  In  this  example,  the  CNS  sub-
network  is  composed  of  109  nodes  and  71  edges.  Ten  thousand
random  networks  with  the  same  number  of  nodes  (i.e.  109)  were
generated and the distribution  of  edges was plotted along with the
number of edges of the relevant sub-network (i.e. 71).  A p-value was
computed to evaluate the probability that this number of edges was
seen by chance. 
 
Figure  3.  Cell-specific  gene  sub-networks  of  GW  associated
regions  (r2>0.5).  Graphs  correspond  to  the largest  connected
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component in each cell/tissue bucket. Nodes represent proteins and
edges represent interactions. For each cell type the PRE is proportional
to  the  color  intensity  (dark:  high;  light:  low).  Genes/proteins  are
organized according to their cellular distribution. The histogram next to
each sub-network shows the distribution of  the number of  edges of
10,000  randomly  generated  networks.  The  red  arrows  denote  the
number of edges observed in the corresponding sub-network and the
p-value, the probability of observing a more extreme number of edges
in a randomly generated network. Panel A: B cells; Panel B: T cells;
Panel  C:  monocytes.  An  asterisk  is  placed  next  to  genes/proteins
exclusively  observed in  that cell  type. Panel  D shows an aggregate
(common) module present in all three cell types. A pie chart describes
the  GO:  molecular  functions  assigned  to  these  genes  and  a  table
describes the nine PANTHER pathways that were significantly enriched.
 
Figure  4.  Individualized  PRE  computations  for  three
representative  associated  regions. Each  row  represents  an
individual  (out  of  2,370  cases  and  412  controls),  and  each column
represents  a gene within  the associated region.  Region 9 (Panel  A)
contains the gene EOMES (green boxes), region 21 includes CD40 (pink
boxes) (Panel C) and region 53 (Panel C) the FC receptor-like cluster
(yellow  boxes).  The  leftmost  column  denotes  subject  status  (red:
cases; green: controls)
51
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
Figure 5. Select case-control intra-individual MS-risk networks.
A. Number of edges in the largest connected component (LCC) of the
network  generated  among  proteins  (genes)  with  high  PRE  (>25th
percentile)  in  2370  patients  and  412  healthy  controls  (GW_r2>0.5).
Each row represents a subject, each column represents a cell type (B:
B cell; T: T cell; M: monocyte; C: CNS). The leftmost column indicates
subject  status  (red:  cases;  green:  controls).  B. Representative  sub-
networks from subjects at the extremes of the distribution for E-LCC for
each cell type. For each network, the number of nodes (N), edges (E)
and percentile relative to all subjects (P) is indicated. The intensity of
node color is proportional to the PRE of each gene in the corresponding
cell type. 
 
Figure 6. Heterogeneity in intraindividual MS-risk networks 
Intraindividual cell-specific networks of four representative MS subjects
showing heterogeneity of risk across all cell types. A. Cell specific risk
networks for subject_id: 201327986.  B. Cell specific risk networks for
subject_id:  201101471.  C. Cell  specific  risk  networks  for  subject_id:
201102205.  D. Cell specific risk networks for subject_id: 201101897.
For each subject, the most connected risk network (number of edges in
the  highest  percentile  across  all  subjects)  is  highlighted  within  a
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colored box. For each network, the number of nodes (N), edges (E) and
percentile relative to all subjects (P) is indicated. The intensity of node
color is proportional to the PRE of each gene in the corresponding cell
type.  M:  monocyte,  green;  T:  T  cells,  red;  B:  B  cells,  blue,  C:  CNS,
yellow
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